Nisa Investment Advisors’s UroGen Pharma URGN Stock Holding History

Nisa Investment Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.9K	Buy	595 +131	+28%	+$3.55K	﹤0.01%	2181
2026 Q1	$8.34K	Hold	464	–	–	﹤0.01%	2302
2025 Q4	$10.9K	Sell	464 -188	-29%	-$4.08K	﹤0.01%	2177
2025 Q3	$13K	Buy	652 +634	+3,522%	+$11.4K	﹤0.01%	2180
2025 Q2	$247	Sell	18 -10	-36%	-$96	﹤0.01%	2968
2025 Q1	$310	Sell	28 -2	-7%	-$21	﹤0.01%	2867
2024 Q4	$320	Sell	30 -137	-82%	-$1.64K	﹤0.01%	2889
2024 Q3	$2.12K	Buy	167 +92	+123%	+$1.37K	﹤0.01%	2385
2024 Q2	$1.26K	Buy	75 +58	+341%	+$825	﹤0.01%	2471
2024 Q1	$255	Buy	+17	New	+$278	﹤0.01%	2608
2020 Q3	–	Sell	-3,976	Closed	-$104K	–	2270
2020 Q2	$104K	Sell	3,976 -234	-6%	-$5.72K	﹤0.01%	1435
2020 Q1	$75K	Hold	4,210	–	–	﹤0.01%	1447
2019 Q4	$140K	Hold	4,210	–	–	﹤0.01%	1384
2019 Q3	$100K	Buy	+4,210	New	+$138K	﹤0.01%	1458

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Nisa Investment Advisors's URGN Position: Q2 2026 in Review

Nisa Investment Advisors increased its UroGen Pharma (URGN) stake by 28% in Q2 2026, buying an estimated $3.55K and bringing the position to 595 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2181.

Nisa Investment Advisors first reported a position in URGN in Q3 2019 and has held it in 14 quarters since. The position peaked at $140K in Q4 2019. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Nisa Investment Advisors held 595 shares of UroGen Pharma worth $21.9K as of Q2 2026.
Nisa Investment Advisors bought 131 UroGen Pharma shares in Q2 2026, an estimated $3.55K.
UroGen Pharma made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2181 holding.
Nisa Investment Advisors first reported a position in UroGen Pharma in Q3 2019 and has held it in 14 quarters since.
Nisa Investment Advisors's UroGen Pharma position peaked at $140K in Q4 2019.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.